From €855EUR$990USD£740GBP
- Drug Pipelines
- February 2021
- 351 pages
From €6003EUR$6,950USD£5,198GBP
- Report
- February 2021
- 171 Pages
From €3239EUR$3,750USD£2,805GBP
- Report
- April 2021
- 2006 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2001 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2111 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2011 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2157 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2075 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2095 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 2091 pages
€3325EUR$3,850USD£2,880GBP
- Report
- April 2021
- 381 pages
From €4707EUR$5,450USD£4,076GBP
- Report
- April 2021
- 181 pages
From €4275EUR$4,950USD£3,702GBP
- Report
- April 2021
- 129 pages
From €4275EUR$4,950USD£3,702GBP
- Report
- March 2021
- 89 pages
From €3200EUR$3,969USD£2,868GBP
- Report
- March 2021
- 93 pages
From €3200EUR$3,969USD£2,868GBP
- Drug Pipelines
- March 2021
- 60 pages
From €1296EUR$1,500USD£1,122GBP
- Drug Pipelines
- March 2021
- 60 pages
From €1296EUR$1,500USD£1,122GBP
- Drug Pipelines
- March 2021
- 240 pages
From €2591EUR$3,000USD£2,244GBP
- Report
- February 2021
- 110 pages
From €4215EUR$4,880USD£3,650GBP

With low survival rates primary brain cancers such as glioblastoma multiforme (the most common and aggressive of malignant brain tumours) are among the deadliest forms of cancer. Drug development activity is therefore intense in this sector, with resulting business development opportunities. Reports in the Brain Cancer section enable you to explore various facets of the industry from a variety of expert viewpoints, including R&D (clinical trials, drug discovery, etc.), competitive landscape, supply and demand, regional markets, regional market analysis, and much more. Show Less Read more